JP2009502961A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009502961A5 JP2009502961A5 JP2008524206A JP2008524206A JP2009502961A5 JP 2009502961 A5 JP2009502961 A5 JP 2009502961A5 JP 2008524206 A JP2008524206 A JP 2008524206A JP 2008524206 A JP2008524206 A JP 2008524206A JP 2009502961 A5 JP2009502961 A5 JP 2009502961A5
- Authority
- JP
- Japan
- Prior art keywords
- prodrug
- deuterium
- compound
- polymorph
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940002612 prodrug Drugs 0.000 claims 12
- 239000000651 prodrug Substances 0.000 claims 12
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 229910052805 deuterium Inorganic materials 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- -1 or a hydrate Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000021663 Female sexual arousal disease Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims 1
- 201000001068 Prinzmetal angina Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000005485 Thrombocytosis Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 238000007889 carotid angioplasty Methods 0.000 claims 1
- 208000023819 chronic asthma Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 claims 1
- 230000004720 fertilization Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 201000005857 malignant hypertension Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70357005P | 2005-07-29 | 2005-07-29 | |
| US70361205P | 2005-07-29 | 2005-07-29 | |
| PCT/US2006/029461 WO2007016361A2 (en) | 2005-07-29 | 2006-07-28 | Novel pharmaceutical compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009502961A JP2009502961A (ja) | 2009-01-29 |
| JP2009502961A5 true JP2009502961A5 (enExample) | 2009-09-10 |
Family
ID=37709213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008524206A Pending JP2009502961A (ja) | 2005-07-29 | 2006-07-28 | 新規な医薬組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20070037815A1 (enExample) |
| EP (2) | EP2324886A1 (enExample) |
| JP (1) | JP2009502961A (enExample) |
| KR (1) | KR20080047375A (enExample) |
| AU (1) | AU2006275702A1 (enExample) |
| BR (1) | BRPI0615972A2 (enExample) |
| CA (1) | CA2616366A1 (enExample) |
| WO (1) | WO2007016361A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7863274B2 (en) | 2005-07-29 | 2011-01-04 | Concert Pharmaceuticals Inc. | Deuterium enriched analogues of tadalafil as PDE5 inhibitors |
| WO2007070426A2 (en) * | 2005-12-09 | 2007-06-21 | Mayo Foundation For Medical Education And Research | Sexual dysfunction |
| US20090291958A1 (en) * | 2006-06-08 | 2009-11-26 | Auspex Pharmaceuticals, Inc. | Substituted PDE5 inhibitors |
| US8552008B2 (en) | 2006-10-20 | 2013-10-08 | Concert Pharmaceuticals, Inc. | Deuterated 3-(dihydro-1H-pyrazolo[4,3-D]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use |
| US8080549B2 (en) | 2007-01-12 | 2011-12-20 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
| US8071596B2 (en) | 2007-01-12 | 2011-12-06 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
| WO2008100886A1 (en) * | 2007-02-12 | 2008-08-21 | Auspex Pharmaceuticals, Inc. | Preparation and use of deuterated udenafil analogues as highly selective pde5 modulators for the treatment of erectile dysfunction |
| US7608737B2 (en) * | 2007-05-01 | 2009-10-27 | Concert Pharmaceuticasl Inc. | Naphthyl(ethyl)acetamides |
| US20080319086A1 (en) * | 2007-06-20 | 2008-12-25 | Protia, Llc | Deuterium-enriched salmeterol |
| CA2698808A1 (en) * | 2007-09-13 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof |
| WO2009099620A1 (en) * | 2008-02-04 | 2009-08-13 | Concert Pharmaceuticals Inc. | 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use |
| HUP0900231A2 (hu) * | 2009-04-16 | 2010-11-29 | Hyd Rakkutato Es Gyogyszerfejlesztoe Kft | Allergiás betegségek kezelésére, gyógyítására alkalmas készítmények és eljárás azok elõállítására |
| JP2012531433A (ja) * | 2009-06-25 | 2012-12-10 | メドリューション リミテッド | キナーゼ阻害剤としての置換複素環式化合物とその用法 |
| EP2687854A1 (en) * | 2012-07-19 | 2014-01-22 | Chiron AS | Test kit for the quantitative determination of narcotic drugs |
| GB201221032D0 (en) * | 2012-11-22 | 2013-01-09 | Mens Health Ltd | Method of treatment |
| MX2015011456A (es) | 2013-03-13 | 2016-05-31 | Boston Biomedical Inc | Derivados de 3-(arilo o heteroailo) metilenindolino-2-ona como inhibidores de cinasas de la via de las celulas madres cancerosas para el tratamiento del cancer. |
| WO2015089105A1 (en) | 2013-12-09 | 2015-06-18 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| ES2835874T3 (es) | 2014-07-29 | 2021-06-23 | Shenzhen Hightide Biopharmaceutical Ltd | Sales de berberina, sales ursodesoxicólicas y combinaciones, procedimientos de preparación y aplicación de las mismas |
| CA2987109C (en) * | 2015-06-26 | 2020-07-07 | Chongqing University of Arts and Sciences | 6-(benzo[d][1,3]dioxol-5-yl)-2-substituted-2,3,12,12a-tetrahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4(6h,7h)-dione derivatives as phosphodiesterase type-5 inhibitors |
| CN106083720B (zh) | 2016-02-28 | 2018-09-11 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的杂芳基化合物及包含该化合物的组合物及其用途 |
| ES2849560T3 (es) | 2016-05-04 | 2021-08-19 | Genoscience Pharma Sas | Derivados de 2,4-diamino-quinolina sustituidos para su uso en el tratamiento de enfermedades proliferativas |
| EP3456328A4 (en) | 2016-05-10 | 2020-02-26 | Shenzhen Hightide Biopharmaceutical., Ltd. | Composition, and application and pharmaceutical preparation thereof |
| CN108864077B (zh) | 2017-05-12 | 2020-05-22 | 深圳君圣泰生物技术有限公司 | 小檗碱有机酸盐的固体形式及其制备方法 |
| US11440904B2 (en) | 2017-08-28 | 2022-09-13 | Zhihong Chen | Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof |
| WO2019099651A1 (en) * | 2017-11-16 | 2019-05-23 | Agios Pharmaceuticals, Inc. | Methods of using deuterated pyruvate kinase activators |
| SG11202008230PA (en) * | 2018-02-28 | 2020-09-29 | Ferro Therapeutics Inc | Compounds with ferroptosis inducing activity and methods of their use |
| TW202519270A (zh) | 2018-06-07 | 2025-05-16 | 美商思進公司 | 喜樹鹼結合物 |
| KR102841141B1 (ko) | 2018-11-01 | 2025-07-31 | 링크 파마슈티컬스 컴퍼니 리미티드 | 트리사이클릭 야누스 키나제 1 억제제 및 이의 조성물 및 방법 |
| WO2020146845A1 (en) | 2019-01-11 | 2020-07-16 | University Of Rochester | Compositions and methods for treating prostate cancer with enzalutamide and an inhibitor of monoamin oxidase a |
| AU2020216345B2 (en) | 2019-02-01 | 2025-03-20 | Canwell Biotech Limited | Imidazoquinoline amine derivatives, pharmaceutical composition, use thereof |
| US10906923B1 (en) | 2019-02-07 | 2021-02-02 | Canwell Biotech Limited | Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof |
| US11040964B2 (en) | 2019-02-27 | 2021-06-22 | Ferro Therapeutics, Inc. | Compounds and methods of use |
| WO2021062307A1 (en) * | 2019-09-25 | 2021-04-01 | Intra-Cellular Therapies, Inc. | Novel methods |
| CA3152316A1 (en) | 2019-10-04 | 2021-04-08 | Scott C. Jeffrey | Camptothecin peptide conjugates |
| US20230340491A1 (en) | 2020-04-22 | 2023-10-26 | University Of Rochester | Compositions and methods for treating metabolic and cardiovascular diseases |
| WO2022169690A1 (en) | 2021-02-02 | 2022-08-11 | Yanping Kong | Composition and methods for treating cancer |
| US20240293405A1 (en) | 2021-06-22 | 2024-09-05 | Jean Zhao | (1h-pyrrolo[2,3-b]pyridin-1-yl)pyrimidin-2-yl-amino-phenyl-acrylamide inhibitors of egfr for use in the treatment of brain tumors |
| WO2025126109A1 (en) | 2023-12-15 | 2025-06-19 | Ensem Therapeutics, Inc. | Anilino-pyrazole derivatives, compositions and methods thereof |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110099A (en) | 1975-12-17 | 1978-08-29 | Eli Lilly And Company | Novel fluoroalkoxyphenyl-substituted nitrogen heterocycles |
| US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| DE3583799D1 (de) | 1985-01-11 | 1991-09-19 | Abbott Lab Ltd | Feste zubereitung mit langsamer freisetzung. |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| US5169868A (en) | 1991-03-01 | 1992-12-08 | University Of Saskatchewan | Aliphatic propargylamines as specific mao-b inhibitors |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US6143746A (en) | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
| GB9401090D0 (en) * | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| IT1291320B1 (it) | 1997-05-08 | 1999-01-07 | Borregaard Italia Spa | Procedimento per la preparazione di composti aromatici contenenti un sistema eterociclico |
| US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| JP2001520999A (ja) | 1997-10-28 | 2001-11-06 | アシビ， エルエルシー | 女性の性的機能不全の処置 |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| KR100501022B1 (ko) | 1998-07-28 | 2005-07-18 | 다나베 세이야꾸 가부시키가이샤 | 장내 적소 방출형 제제 |
| US20040063719A1 (en) | 1998-08-26 | 2004-04-01 | Queen's University At Kingston | Combination therapy using antihypertensive agents and endothelin antagonists |
| US6455564B1 (en) | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
| JP2002543128A (ja) | 1999-04-30 | 2002-12-17 | リリー アイコス リミテッド ライアビリティ カンパニー | 雌性覚醒障害の処置 |
| DE60039357D1 (de) | 1999-08-03 | 2008-08-14 | Lilly Icos Llc | Pharmazeutische zusammensetzung enthaltend tadalafil |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| UA74826C2 (en) * | 2000-05-17 | 2006-02-15 | Ortho Mcneil Pharm Inc | ?-carboline derivatives as phosphodiesterase inhibitors |
| US7737147B2 (en) | 2000-07-27 | 2010-06-15 | Thomas Nadackal Thomas | Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors |
| US6548508B2 (en) | 2000-10-20 | 2003-04-15 | Pfizer, Inc. | Use of PDE V inhibitors for improved fecundity in mammals |
| IL157253A0 (en) | 2001-02-28 | 2004-02-19 | Merck & Co Inc | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| WO2002068387A2 (en) | 2001-02-28 | 2002-09-06 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| US6892568B2 (en) | 2003-02-03 | 2005-05-17 | Honda Giken Kogyo Kabushiki Kaisha | Noise detection system and method |
| JP4175113B2 (ja) | 2001-03-14 | 2008-11-05 | 小野薬品工業株式会社 | Ｅｐ１アンタゴニストを有効成分として含有するうつ病の治療剤 |
| US7846913B2 (en) | 2003-12-29 | 2010-12-07 | Mcdevitt Jason Patrick | Compositions and methods to treat recurrent medical conditions |
| CA2441792C (en) * | 2001-04-25 | 2010-08-03 | Lilly Icos Llc | Carboline derivatives as inhibitors of phosphodiesterase 5 (pdes) for the treatment of cardiovascular diseases and erectile dysfunction |
| US6737042B2 (en) | 2001-05-24 | 2004-05-18 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| LV12979B (en) | 2001-09-07 | 2003-05-20 | Ivars Kalvins | Pharmaceutical composition |
| US7019010B2 (en) | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
| EP1461022A2 (en) | 2001-12-17 | 2004-09-29 | ALTANA Pharma AG | Use of selective pde5 inhibitors for treating partial and global respiratory failure |
| US20050014848A1 (en) | 2002-01-23 | 2005-01-20 | Pfizer Inc. | Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors |
| US20030235609A1 (en) | 2002-01-25 | 2003-12-25 | Lautt Wilfred Wayne | Use of cholinesterase antagonists to treat insulin resistance |
| US20030181461A1 (en) | 2002-01-25 | 2003-09-25 | Lautt Wilfred Wayne | Use of phosphodiesterase antagonists to treat insulin resistance |
| WO2003101276A2 (en) | 2002-05-22 | 2003-12-11 | Virginia Commonwealth University | Protective effects of pde-5 inhibitors |
| US20040077624A1 (en) | 2002-05-23 | 2004-04-22 | Pfizer Inc. | Novel combination |
| US20040132731A1 (en) | 2002-06-26 | 2004-07-08 | Fox David Nathan Abraham | Novel combination |
| US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| US20040092522A1 (en) | 2002-08-15 | 2004-05-13 | Field Mark John | Synergistic combinations |
| US7369894B2 (en) | 2002-09-06 | 2008-05-06 | Medtronic, Inc. | Method, system and device for treating disorders of the pelvic floor by electrical stimulation of the sacral and/or pudendal nerves |
| US20050070969A1 (en) | 2002-09-06 | 2005-03-31 | Medtronic, Inc. | Method, system and device for treating disorders of the pelvic floor by electrical stimulation and the delivery of drugs to the sacral and pudendal nerves |
| US7427280B2 (en) | 2002-09-06 | 2008-09-23 | Medtronic, Inc. | Method, system and device for treating disorders of the pelvic floor by delivering drugs to various nerves or tissues |
| US6800663B2 (en) | 2002-10-18 | 2004-10-05 | Alkermes Controlled Therapeutics Inc. Ii, | Crosslinked hydrogel copolymers |
| US8133903B2 (en) | 2003-10-21 | 2012-03-13 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases |
| US7659305B2 (en) | 2002-10-31 | 2010-02-09 | Pfizer Inc. | Therapeutic proline derivatives |
| US20040180958A1 (en) | 2002-12-13 | 2004-09-16 | Taylor Charles Price | Method of treatment |
| GB0230025D0 (en) | 2002-12-23 | 2003-01-29 | Pfizer Ltd | Novel pharmaceuticals |
| WO2004069167A2 (en) | 2003-01-31 | 2004-08-19 | Nastech Pharmaceutical Company Inc. | Method and compositions for treating male infertility |
| JP4533590B2 (ja) | 2003-02-28 | 2010-09-01 | ファイザー株式会社 | 脊髄損傷患者における疼痛又は痙性軽減用医薬組成物 |
| WO2004078717A1 (en) | 2003-03-03 | 2004-09-16 | Merck & Co., Inc. | Acylated piperazine derivatives as melanocortin-4 receptor agonists |
| PA8597401A1 (es) | 2003-03-14 | 2005-05-24 | Pfizer | Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep |
| US20040186046A1 (en) | 2003-03-17 | 2004-09-23 | Pfizer Inc | Treatment of type 1 diabetes with PDE5 inhibitors |
| EP1624893A2 (en) | 2003-04-01 | 2006-02-15 | Applied Research Systems ARS Holding N.V. | Inhibitors of phosphodiesterases in infertility |
| CA2528975A1 (en) | 2003-06-10 | 2004-12-16 | Pfizer Inc. | Therapeutic combinations comprising pde inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhoea |
| US20050101608A1 (en) | 2003-09-24 | 2005-05-12 | Santel Donald J. | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
| US7745630B2 (en) * | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
-
2006
- 2006-07-28 WO PCT/US2006/029461 patent/WO2007016361A2/en not_active Ceased
- 2006-07-28 EP EP11155798A patent/EP2324886A1/en not_active Withdrawn
- 2006-07-28 EP EP06788821A patent/EP1909576A4/en not_active Withdrawn
- 2006-07-28 KR KR1020087004869A patent/KR20080047375A/ko not_active Withdrawn
- 2006-07-28 CA CA002616366A patent/CA2616366A1/en not_active Abandoned
- 2006-07-28 AU AU2006275702A patent/AU2006275702A1/en not_active Abandoned
- 2006-07-28 BR BRPI0615972-9A patent/BRPI0615972A2/pt not_active Application Discontinuation
- 2006-07-28 JP JP2008524206A patent/JP2009502961A/ja active Pending
- 2006-07-31 US US11/498,305 patent/US20070037815A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009502961A5 (enExample) | ||
| JP7169412B2 (ja) | 抗癌活性及び抗増殖活性を呈する２－アミノピリミジン－６－オン及び類似体 | |
| JP2009502963A5 (enExample) | ||
| RU2769607C2 (ru) | N-ацил-N'-(пиридин-2-ил) карбамиды и их аналоги, проявляющие противораковую и антипролиферативную активность | |
| TWI549953B (zh) | ７－環戊基－２－（５－哌－１－基－吡啶－２－基胺基）－７ｈ－吡咯并［２，３－ｄ］嘧啶－６－羧酸二甲醯胺之鹽類及其製備方法 | |
| JP2010533203A5 (enExample) | ||
| JP2016034968A5 (enExample) | ||
| JP4477097B2 (ja) | 中枢神経系障害の治療のための（２ｓ）−（４ｅ）−ｎ−メチル−５−［３−（５−イソプロポキシピリジン）イル］−４−ペンテン−２−アミンの多形形態 | |
| CN101336238A (zh) | 新颖的二环羰基氨基吡啶-2-甲酰胺或3-二环羰基氨基吡嗪-2-甲酰胺 | |
| JP2018131460A (ja) | 横隔膜機能を向上させるための方法 | |
| JP2022166179A (ja) | アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス | |
| JP7680619B2 (ja) | Ｐａｒｐ１阻害薬及びその使用 | |
| HUP0402245A2 (hu) | Glikogén-szintáz-kináz-3béta inhibitor hatású pirimidinil-aminobenzamid-származékok, alkalmazásuk, ezeket tartalmazó gyógyszerkészítmények és eljárás az előállításukra | |
| JP2008510762A5 (enExample) | ||
| JP2013529647A5 (enExample) | ||
| JP2006143737A5 (enExample) | ||
| KR100767854B1 (ko) | 피리딜옥시메틸 및 벤즈이속사졸 아자비시클릭 유도체 | |
| RU2004133811A (ru) | Новые соединения | |
| JP5710490B2 (ja) | （ｒ）−５−（（ｅ）−２−（ピロリジン−３−イルビニル）ピリミジンの合成および新規の塩形態 | |
| CN114206836B (zh) | 新型吡咯化合物 | |
| JPWO2019220390A5 (enExample) | ||
| JP2019508385A (ja) | テネリグリプチンのシュウ酸塩およびその溶媒和物、中間体、その調製方法およびマーカー | |
| CN114127061A (zh) | (r)-4-(1-((3-(二氟甲基)-1-甲基-1h-吡唑-4-基)磺酰基)-1-氟乙基)-n-(异噁唑-3-基)哌啶-1-甲酰胺的多晶型物形式 | |
| CN118063393A (zh) | 2,4-二氨基嘧啶类衍生物及其制备方法与应用 | |
| JP2007514791A (ja) | Ｐ３８ｍａｐキナーゼインヒビターであるｂｉｒｂ７９６の多形 |